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Adenosine is a metabolite, which has long been implicated in a variety of inﬂamma-
tory processes. Inhaled adenosine provokes bronchoconstriction in asthmatics or chronic
obstructive pulmonary disease patients, but not in non-asthmatics. This hyper responsive-
ness to adenosine appears to be mediated by mast cell activation. These observations
have marked the receptor that mediates the bronchoconstrictor effect of adenosine on
mast cells (MCs), as an attractive drug candidate. Four subtypes (A1, A2a, A2b, and A3) of
adenosine receptors have been cloned and shown to display distinct tissue distributions
and functions. Animal models have ﬁrmly established the ultimate role of the A3 adeno-
sine receptor (A3R) in mediating hyper responsiveness to adenosine in MCs, although the
inﬂuence of the A2b adenosine receptor was conﬁrmed as well. In contrast, studies of the
A3R in humans have been controversial. In this review, we summarize data on the role of
different adenosine receptors in mast cell regulation of inﬂammation and pathology, with
a focus on the common and distinct functions of the A3R in rodent and human MCs. The
relevance of mouse studies to the human is discussed.
Keywords: mast cells, adenosine, A3 adenosine receptor, HMC-1, RBL-2H3
THE MAST CELL
Mast cells (MCs) are hematopoietic-derived cells that play impor-
tant physiological roles in innate and adaptive immunity, as well as
inwoundhealing (Galli,1997;Metcalfe et al., 1997;Noli andMiolo,
2001; Weller et al., 2006; Metz and Maurer, 2007; Shelburne and
Abraham, 2011). Arising from committed progenitors (CD34+,
c-kit positive cells) in the bone marrow (Rodewald et al., 1996),
MCs progenitors pass through the vascular space, entering the
tissues, where they complete their differentiation and maturation
process in situ (Metcalfe et al., 1981, 1997; Galli, 1997). Mature
MCs typically present widespread plasma membrane processes,
round nuclei, and numerous electron-dense cytoplasmic secretory
granules. Growth, survival, differentiation, and homing are depen-
dent on SCF-dependent c-kit signaling (Metcalfe et al., 1981, 1997)
and accordingly, gain of functions mutations in the c-kit receptor
result inmastocytosis (Lim et al., 2008; Fritsche-Polanz et al., 2010;
Valent et al., 2011).
Human and rodent mature MCs are classiﬁed into one of two
categories, based on phenotypic, biochemical, and functional dif-
ferences. In rodents, MCs are classiﬁed as connective tissue type
MCs (CTMCs), and include primarily skin MCs and cells of the
peritoneal cavity, and mucosal MCs (MMCs), which are asso-
ciated with the mucosa of the digestive tract or lungs (Welle,
1997; Bischoff and Krämer, 2007). In human, two types of MCs
have been categorized based on their neutral protease composi-
tions: MCTC contain the neutral proteases tryptase and chymase,
whereas MCT contain only tryptase (Irani et al., 1986; Welle,
1997). Both types of MCs express on their plasma membrane
FcεRI receptors, the high-afﬁnity receptors for the Fc region of
monomeric Immunoglobulin E (IgE). In tissues, MCs are dis-
tributed at interfaces between the outside world and the internal
milieu, consistent with their immune tasks in host defense mech-
anisms. MCs are also found near blood and lymphatic vessels
(Kunder et al., 2011) as well as in close proximity to nerves
(Bienenstock et al., 1991; Theoharides et al., 2006).
Mature MCs store in their cytoplasmic secretory granules
inﬂammatory mediators, including vasoactive amines such as
histamine and serotonin, multiple proteases such as tryptase
and chymase, mentioned above, and lysosomal hydrolases such
as β-hexosaminidase and cathepsin D (Schwartz and Austen,
1980). MCs secretory granules also contain proteoglycans, such as
heparin and chondroitin sulfate E, and polyamines, which play a
role inproteases storage in secretory granules (Garcia-Faroldi et al.,
2010). Some cytokines, including tumor necrosis factor (TNF-α)
and basic ﬁbroblast growth factor (bFGF) are also prestored in the
secretory granules (Ribatti et al., 2002; Olszewski et al., 2007).
MCs AS MEDIATORS OF ALLERGIC AND INFLAMMATORY
DISEASES
Despite their beneﬁcial physiological roles in immunity and
wound healing, MCs are best known for their involvement in
allergic and inﬂammatory diseases, including autoimmune and
neurodegenerative diseases and cancer, where they contribute
signiﬁcantly to the complexity of these diseases (Galli, 1997;
Theoharides and Kalogeromitros, 2006; Bischoff, 2007). Allergy
involves the activation and subsequent degranulation of MCs,
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where activation can be triggered by a variety of external stimuli
(Figure 1). The immune trigger involves production of IgE class
antibodies, speciﬁc for a wide range of allergens, IgE binding to the
FcεRI, followed by their allergen-induced cross-linking and recep-
tor aggregation leading to cell activation (Turner and Kinet, 1999;
Siraganian, 2003; Gilﬁllan and Tkaczyk, 2006; Rivera and Gilﬁllan,
2006; Wilson et al., 2011). In addition, MCs can be triggered in
an IgE-independent fashion, by a variety of soluble stimuli (see
below), as well as through cell interactions with neighboring cells
including ﬁbroblasts, eosinophils,T cells, andnerve cells (Askenase
et al., 1980; Baram et al., 2001; Garbuzenko et al., 2002; Puxeddu
et al., 2005; Figure 1). These interactions are complex involving
feedback loops. For example, MCs activate eosinophils, which in
turn release proteins that further activate MCs (Puxeddu et al.,
2005).
MCs MECHANISMS OF SECRETION
When activated, MCs release the contents of their secretory
granules within seconds to minutes of trigger. Depending on
the strength of the external signal or the stimulus type, release
may occur by kiss-and-run exocytosis that partially releases the
FIGURE 1 | Complexity of MC activation. A scheme illustrating the
multiple stimuli that can activate MCs. The latter include the immunological,
IgE-mediated pathway, interactions with neighboring cells, such as
eosinophils, T cells, and ﬁbroblasts, pathogens that act throughTLRs, the
c-kit ligand SCF, and numerous stimuli that activate G-proteins, either
directly (e.g., basic secretagogues such as the synthetic c48/80) or by
binding to GPCRs (e.g., adenosine, complement derived peptides,
prostaglandins such as PGE2, cytokines, and more). Depending on the
stimulus type, activated MCs may either release preformed mediators,
packaged in secretory granules (class I mediators) as well newly
synthesized mediators, including metabolites of arachidonic acid (AA, class
II mediators, such as prostaglandins and leukotrienes), cytokines, and
chemokines (class III mediators), or may only release a subset of
mediators. In some cases, the distinct stimuli interact synergistically
resulting in an ampliﬁed response.
secretory granule cargo through a relative narrow and transient
fusion pore; full exocytosis, when fusion of plasma membrane
docked secretory granules, with the plasma membrane, allows
complete expulsion of their contents, and thirdly, compound exo-
cytosis, also termedanaphylactic degranulation, themost extensive
mode of cargo release, that involves fusion of the secretory gran-
ule membrane with the plasma membrane and release of secretory
granule contents, as well as homotypic fusion between secretory
granules by mechanisms whose details are still largely unresolved
(Alvarez De Toledo and Fernandez, 1990; Blank, 2011; Woska
and Gillespie, 2012). In addition, upon activation, MCs also pro-
duce and release arachidonic acid (AA) metabolites including
leukotrienes and prostaglandins as well as multiple cytokines and
chemokines (Metcalfe et al., 1981, 1997; Wasserman, 1983; Galli
et al., 1991; Ogawa and Grant, 2007). Also formed are growth fac-
tors such asVascular endothelial growth factor (VEGF), a cytokine
crucial to angiogenesis, and the growth of blood vessels (Detoraki
et al., 2009; García-Román et al., 2010) and NGF (Xiang and
Nilsson, 2000; Cantarella et al., 2011). Notably, the repertoire of
mediators released by MCs as well as their responsiveness to exter-
nal ligands may vary dependently on the MC type or stimulus
nature. Indeed,MCs are tunable cells (Galli et al., 2005) and under
speciﬁed conditions can be programmed to selectively release a
subset of mediators with no massive degranulation. Such selective
secretion, termed piecemeal degranulation (PMD), is primarily
linked with chronic inﬂammation and accounts for MCs involve-
ment in inﬂammatory diseases and cancer (Dvorak and Kissell,
1991;Crivellato et al., 2003;Theoharides et al., 2007;Ribatti, 2011).
Unlike exocytosis, PMD involves budding of vesicles, carrying the
selective cargo to be released, from the secretory granule, and their
transport and fusion with the plasma membrane. This type of
secretion is also characterized by crosstalk with the endocytic sys-
tem, whereby following their fusion with the plasma membrane
and release of contents, these vesicles recycle to the secretory gran-
ule by means of endocytosis and subsequent fusion (Dvorak et al.,
1992; Crivellato et al., 2003; Ribatti and Crivellato, 2009; Ribatti,
2011). The molecular mechanisms of PMD remain largely elusive.
Upon their release to the extracellular milieu, preformed and
newly synthesizedmediators affectmultiple target organs and cells
giving rise to an immediate inﬂammatory response followed by the
progression of a tremendously ampliﬁed late-phase inﬂammatory
response, which may acquire a chronic nature. The wide spectrum
of biologically active substances produced and released by MCs
thus contributes to the complexity of the allergic diseases. More-
over, an appreciable fraction of mediators released by activated
MCs, acts in an autocrine manner to activate MCs and amplify
their signaling outputs (Gilﬁllan et al., 2009). Such is also the case
of adenosine, whose function in MCs is the focus of the present
review.
NON-IMMUNOLOGICAL ACTIVATION OF MCs
Multiple and diverse stimuli can activate MCs independently of
IgE (Lagunoff et al., 1983; Bhattacharyya et al., 1998; Theoharides
et al., 2007). Already mentioned are neighboring cells and SCF,
that by binding to the c-kit receptor, a member of the receptor
tyrosine kinase (RTK) family of receptors, transmits signals for
MC survival (Iemura et al., 1994), induces direct degranulation of
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rat peritoneal MCs (RPMCs; Taylor et al., 1995), and synergizes
with the immunological, FcεRI mediated response, in stimulating
degranulation, and cytokine release from bone marrow derived
MCs (BMMCs) or human MCs (Coleman et al., 1993; Hundley
et al., 2004). Toll like receptors (TLRs) serve as pattern-recognition
receptors and mediate MCs responses to pathogens (Qiao et al.,
2006; Mrabet-Dahbi et al., 2009; Avila and Gonzalez-Espinosa,
2011; Lorentz, 2011; Wesolowski and Paumet, 2011; Chan et al.,
2012). Different TLRs are expressed in the different MCs types
(reviewed in Novak et al., 2010), that dependently on the lig-
and/receptor complex type, display distinct modulator functions
on the FcεRI mediated responses (Qiao et al., 2006). Finally, and
particularly intriguing is the large number of non-immunological
pathways that involve activation of G-proteins, either directly
(Repke and Bienert, 1987;Aridor and Sagi-Eisenberg, 1990;Aridor
et al., 1990, 1993; Mousli et al., 1990), or through binding to G-
protein coupled receptors (GPCRs; Okayama et al., 2008; Druey,
2009).
Receptor mimetic activation of G-proteins was demonstrated
in RPMCs that seem to display unique membrane characteristics
that allow molecules comprising a hydrophobic stretch combined
with a positively charged domain, to penetrate the membrane
(Ortner and Chingell, 1981) and interact directly with G-proteins
(Higashijima et al., 1988; Aridor et al., 1990). This group of mol-
ecules, collectively known as the basic secretagogues of MCs, were
recognized as early as 1951 as potent IgE-independent activators of
MCs that triggered exocytosis in a pertussis toxin (Ptx) sensitive
manner, therefore implicating Gi protein(s) as essential media-
tors of their triggered exocytosis (Nakamura and Ui, 1984, 1985).
Indeed, the large repertoire of molecules that constitute this fam-
ily of stimuli, including neuropeptides, opiates, and the synthetic
polyamine compound 48/80 (c48/80; Lagunoff et al., 1983), their
common structural features and the fact that micromolar con-
centrations are required to evoke their biological activity, have
suggested that members of this family trigger MC activation in
a receptor-independent manner (Repke and Bienert, 1987; Ari-
dor and Sagi-Eisenberg, 1990; Aridor et al., 1990, 1993; Mousli
et al., 1990). More recent data demonstrated expression of a low-
speciﬁcity activation site for basic secretagogues also in human
MCs (LAD-2 and CD34-derived) and have identiﬁed this site as
MrgX2, a member of the Mrg class of GPCRs (Tatemoto et al.,
2006; Kashem et al., 2011; Subramanian et al., 2011). Whether or
not RPMCs express MrgX2 is presently unknown. However, it is
noteworthy that while the basic secretagogues-stimulated signal-
ing networks and outputs, including degranulation, Ca2+ rise and
activationof theMAPkinases, are Ptx sensitive,Ptx inhibitsMrgX2
mediated degranulation in human MCs, but has no effect on Ca2+
inﬂux, suggesting that in sharp contrast to the exclusive activation
of Gi proteins by basic secretagogues in RPMCs, the MrgX2 cou-
ples to both Gi and presumably to Gq in human MCs (Sheﬂer
et al., 1999; Sheﬂer and Sagi-Eisenberg, 2002; Subramanian et al.,
2011).
We identiﬁed the G-protein Gi3 as the principal mediator of
basic secretagogues-induced exocytosis in RPMCs by demonstrat-
ing that a peptide comprising the 10 C-terminal amino acids of
Gαi3 (KNNLKECGLY), introduced into permeabilized cells, could
inhibit c48/80-induced histamine release (Aridor et al., 1993). We
then engineered a cell permeable version of this peptide, in which
an importation sequence derived from the signal sequence of the
Kaposi ﬁbroblast growth factor (AAVALLPAVLLALLAP)was fused
to Gαi3 C-terminal sequence, giving rise to a 16 amino acids
peptide, we termed ALL1. We could show that ALL1 efﬁciently
penetrates into intact RPMCs and blocks c48/80-induced hista-
mine secretion, protein tyrosine phosphorylation, and release of
Prostaglandin D2 (PGD2) in a dose dependent fashion (Sheﬂer
et al., 2008).
Mast cells can also be activated by ligands that bind to classi-
cal, high-afﬁnity, GPCRs. Included are some basic secretagogues,
such as the neuropeptide substance P, that activates human or
MMCs by binding to a tachykinin class receptor (Asadi et al.,
2012), as well as prostaglandins, sphingosine-1-phosphate, hista-
mine, cytokines, adenine nucleotides, complement, and adenosine
(reviewed in Okayama et al., 2008; Druey, 2009; Gilﬁllan et al.,
2009). This list includes mediators that are also released by acti-
vated MCs, or whose concentrations are elevated consequently
to tryptase release (e.g., C3a, generated upon complement pro-
cessing; Ali, 2009). These ligands may thus act in a paracrine or
autocrine fashion to amplify or modulate the MC cellular inﬂam-
matory responses (reviewed in Okayama et al., 2008; Druey, 2009;
Gilﬁllan et al., 2009).
ADENOSINE AND MC-MEDIATED INFLAMMATION
Non-immunological activation of MCs is primarily linked with
chronic inﬂammation and accounts for MC involvement in
autoimmune and degenerative diseases and cancer (Theoharides
and Kalogeromitros, 2006; Theoharides et al., 2007; Ribatti and
Crivellato, 2009; Ribatti, 2011). In most cases, the underlying
mechanism involves stimulation of selective release of a subset
of mediators, with no massive degranulation by PMD, described
above. For example, such is the case of corticotropin-releasing
hormone (CRH) or prostaglandin E2 (PGE2), that stimulate
release of VEGF without degranulation from the human mast
cell line (HMC-1) or human umbilical cord blood derived MCs
(HUCBMCs; Cao et al., 2006). Adenosine, the focus of this review,
is produced both intracellularly and extracellularly under condi-
tions of increased energy consumption such as stress or hypoxia
that develop at sites of inﬂammation and injury (Linden, 2001;
Bours et al., 2006). Hence, during systemic inﬂammation, the
circulating adenosine concentration increases rapidly (Ramakers
et al., 2011).Adenosine then functions in an autocrine or paracrine
fashion through binding to four GPCRs: the A1, A2a, A2b, and
A3 receptors that display distinct pharmacological characteristics.
The A1R and A2a subtypes have the highest afﬁnity for adenosine,
whereas the afﬁnity for adenosine of the A2b and A3 receptors
is signiﬁcantly lower (Linden, 2001). Individual receptors can
be speciﬁcally activated or blocked by type speciﬁc agonists or
antagonists (Table 1). Adenosine receptors also couple to different
G-proteins, whereby the A1 and A3 receptors couple to Ptx sensi-
tive Gi proteins, while the A2aR couples to Gs and the A2bR to Gs
andGq/G11 (reviewed in Brown et al., 2008). Accordingly, engage-
ment of the adenosine receptor subtypes evokes distinct cellular
responses (Table 1).
Adenosine has been long implicated in a variety of inﬂam-
matory processes, including allergy and especially asthma (Bours
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et al., 2006; Spicuzza et al., 2006; Matera and Polosa, 2007; Brown
et al., 2008; Polosa and Blackburn, 2009). That MCs mediate
adenosine responses in allergic inﬂammationwas ﬁrst indicated by
the ability of adenosine to potentiate IgE-inducedmediator release
from rodent MCs (Holgate et al., 1980). The physiological rele-
vance to human was then advocated by observations documenting
the ability of adenosine to provoke bronchoconstriction in atopic
and asthmatic individuals, but not in normal subjects, a phenome-
non referred to as adenosine hyper responsiveness (AHR; Cushley
and Holgate, 1985). Furthermore, elevated levels of adenosine are
found in bronchoalveolar lavage ﬂuid and exhaled breath conden-
sates of allergic inﬂammation patients (Driver et al., 1993; Huszar
et al., 2002; Vass et al., 2006) and inhalation of adenosine by asth-
matics leads to increased levels of MC mediators such as histamine
and tryptase in bronchoalveolar ﬂuid. Finally, blockers of medi-
ators released by activated MCs inhibit the bronchoconstrictor
response to adenosine in asthma (Meade et al., 2001; Spicuzza et al.,
2006). This notionwas supported further by the ﬁndings thatMCs
express the two ecto-enzymes, CD73, a nucleoside triphosphate
phosphohydrolase, and CD39, an ecto-5′-nucleotidase, that by
concerted conversion of adenine nucleotides to adenosine increase
its extracellular concentrations (Linden, 2001); prominent secre-
tion of adenosine is observed in activated MCs (Marquardt et al.,
1984) as well as the rat derived mast cell line, RBL-2H3 (Lloyd
et al., 1998); and thatMCs express adenosine receptors (Carruthers
and Fozard, 1993). However, the identity of the speciﬁc adenosine
receptor(s) that mediate(s) adenosine triggered MCs responses
remained elusive.
THE A3R AS MEDIATOR OF MCs-DEPENDENT
INFLAMMATION
Animal models have substantiated the central role played by acti-
vated MCs in mediating AHR and have identiﬁed the A3R as
the major contributor. Speciﬁcally, airway responses elicited by
adenosine are signiﬁcantly attenuated in A3R- or MC-deﬁcient
mice (Tilley et al., 2003). Furthermore, aerosolized adenosine-
5′N -ethylcarboxamide (NECA; a non-selective ligand) induces
hyper responsiveness in wt or A1R-deﬁcient mice, but not in
A3R knockout mice (Hua et al., 2008) and AHR develops in
MC-deﬁcient mice that are reconstituted with wt, but not with
A3R−/− MCs (Hua et al., 2008). In vitro studies employing iso-
lated MCs and selective receptor agonists have substantiated this
notion further by demonstrating that adenosine directly stim-
ulates murine lung MCs degranulation by activating the A3R
(Zhong et al., 2003). In a similar fashion, intravenous applica-
tion of N6-2-(4-aminophenyl)ethyladenosine (APNEA; Fozard
et al., 1996) or intradermal introduction of the A3R agonist 2-
(1-Hexynyl)-N -methyladenosine (IB-MECA; Reeves et al., 1997)
to rats, respectively induced MC degranulation or plasma protein
extravasation (PPE), conﬁrming a key role for the A3R in medi-
ating MCs responses. However, exposure of rat isolated pleural
MCs, RBL-2H3 cells, or BMMCs to IB-MECA, enhanced FcεRI-
induced secretion, but failed to induce directly such degranulation
(Ramkumar et al., 1993; Reeves et al., 1997; Yamano et al., 2005,
2006). Therefore, collectively these studies have ﬁrmly established
the involvement of the A3R in MC degranulation. Yet, they have
also indicated that whether or not engagement of the A3R sufﬁces
to promote MCs degranulation, or whether additional signals,
stemming from the FcεRI or the other adenosine receptors (i.e.,
A2bR, see below), are required, depends on the MC type, the tis-
sue it resides in, and perhaps even the species or the mouse strain
(Meade et al., 2001).
In addition to direct or synergistic effects on MC degranula-
tion, occupiedA3R mediates the stimulatory impacts of adenosine
and the FcεRI on MCs migration (Endo et al., 2005; Kitaura et al.,
2005; Kuehn et al., 2010). Since MC migration is an important
mechanism toward their accumulation at allergic inﬂammatory
sites, this activity of the A3R further adds to its pro-inﬂammatory
functions.
Genetic and pharmacological approaches have assigned the
A2aR anti-inﬂammatory properties (Bonneau et al., 2006;Nadeem
et al., 2007; Haskó and Pacher, 2008), and have revealed a com-
plex function of the A2bR (Table 1). Hence, BMMCs derived
from A2bR knockout mice demonstrated increased sensitivity to
IgE-mediated anaphylaxis (Hua et al., 2007), but work in the
adenosine deaminase (ADA)-deﬁcient model, pharmacological
studies employing the A2bR antagonist CVT-6883 in a mouse
model of ragweed sensitization and challenge, and in vitro studies
on BMMCs derived from A2bR knockout mice, supported a pro-
inﬂammatory role of this receptor in mediating MC functions,
and have particularly placed this receptor in playing a role in late-
stages or chronic features of airway diseases such as asthma (Sun
et al., 2006; Mustafa et al., 2007; Ryzhov et al., 2008; Polosa and
Blackburn, 2009).
STUDIES IN HUMAN MCs
Studies employing human lung MCs demonstrated that at low
concentrations, adenosine potentiated degranulation of immuno-
logically activated MCs, whereas at higher concentrations a coun-
teractive inhibitory process took place (Peachell et al., 1988, 1991).
These responses were interpreted as being mediated by the A2
type receptors. Consistent with these results, studies with HMC-
1, a human mast cell line, conﬁrmed the expression of both the
A2a and A2b receptors, where A2bR mRNA was eightfold more
abundant than A2a mRNA (Meade et al., 2002). A2bR stimu-
lation resulted in the release of IL-4, IL-8, and IL-13, cytokines
linked with allergic inﬂammation and asthma (Feoktistov and
Biaggioni, 1995; Ryzhov et al., 2004, 2006). Taken together with
the demonstration that enprofylline and theophylline, two anti
asthmatic drugs, block adenosine-induced release of IL-8 from
HMC-1 cells, these results implicated the A2bR as the principal
mediator of AHR in humans (Haskû et al., 2009). Thus, while the
studies in rodent MCs have provided unequivocal evidence for the
involvement of the A3R in mediating the adenosine bronchocon-
strictor response, this role was questioned in human MCs and was
rather assigned to theA2bR. Moreover, studies in humans demon-
strating A3R-mediated inhibition of neutrophils degranulation
(Bouma et al., 1997) and eosinophils chemotaxis (Knight et al.,
1997; Walker et al., 1997), have suggested that the A3R may play
an anti-inﬂammatory role.However, against this dogma are results
obtained in HMC-1 cells, where the data clearly indicate that IL-8
release can also be stimulated by IB-MECA (Meade et al., 2002).
The latter was approximately ﬁvefold less potent than the A2bR
agonist, but this lower potency was consistent with A3R being
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eightfold less abundant than theA2bR in this cell line (Meade et al.,
2002). Further analyses revealed that activation of A3R in HMC-1
cells induces the expression, thoughnot secretion,of angiopoietin-
2, by a mechanism, which did not involve inhibition of adenylyl
cyclase or activation of PLC (Feoktistov et al., 2003). Activation of
A2b could enhance secretion of the angiogenic factor, but a max-
imal response depended on the simultaneous activation of both
the A2b and A3 receptors (Feoktistov et al., 2003).
Employing the HMC-1 cell line, we found no evidence for A3R
stimulated degranulation or cytokine release (Baram et al., 2010).
However, a wide-genome screen demonstrated up-regulation of
genes that play important roles in allergic inﬂammation and
asthma upon A3R activation (Baram et al., 2010). The latter
included cytokines such as IL-8, chemokines, growth factors, and
angiogenic factors (Baram et al., 2010). Therefore, these studies
supported a pro-inﬂammatory, modulator role of this receptor in
human MCs. Consistent with this premise we also obtained evi-
dence for the activation of theA3R, in an autocrinemanner, in cells
activated through contact with T cell derived membranes (Baram
et al., 2010).
Because HMC-1 cells do not express the FcεRI, the modulator
action of adenosine on immunologically stimulated MCs could
not be investigated in this model. However, this question was
addressed using HUCBMCs, in which only an inhibitory A2aR-
mediated function could be detected (Suzuki et al., 1998). Specif-
ically, exposure of HUCBMCs to 4-[2-[[6-Amino-9-(N -ethyl-β-
d-ribofuranuronamidosyl)-9H -purin-2-yl]amino]ethyl]benzene
propanoic acid hydrochloride (CGS21680), a speciﬁc agonist of
the A2aR, resulted in the inhibition of tryptase release (Suzuki
et al., 1998). Accordingly, RT-PCR analysis indicated the domi-
nant expression of A2aR mRNA, though A3R mRNA was detected
as well (Suzuki et al., 1998). Using the same model of HUCBMCs,
a biphasic effect of adenosine was noted on anti-IgE-induced
degranulation, where potentiation was assigned to the A1R and
inhibition of the anti-IgE-induced responses to the A2bR (Yip
et al., 2009). Finally, in a recent study, where HUCBMCs were
treated for 3 days with IL-4 and IgE, addition of adenosine poten-
tiated anti-IgE-induced degranulation and this enhancement was
reduced or abolished by A2bR antagonists or A2b speciﬁc siRNA
implicating the A2bR in mediating the adenosine synergistic
response (Hua et al., 2011). In same study, neither selective A3R
agonist, nor an A3R antagonist displayed any activity. In fact,
in human MC cultures derived from CD34+ peripheral blood
progenitor cells (HuMCs) or the LAD-2 cells, adenosine failed
to effect degranulation (Kuehn et al., 2011). But then contradic-
tory to these observations, a recent study employing human lung
derived MCs demonstrated potentiation of IgE-induced degran-
ulation by adenosine in a Ptx sensitive fashion. Furthermore, an
A3R-speciﬁc agonist recapitulated this potentiation (Gomez et al.,
2011). Notably, these lung derived MCs were shown to express
threefold more A3R mRNA than do skin MCs (Gomez et al.,
2011).
Taken together, these studies illustrate the difﬁculties faced
studying human MC A3R, whose properties might be altered by
physiological/environment speciﬁc responses not recapitulated in
cell lines or even primary MCs (Gessi et al., 2008).
A3R SIGNALING IN RODENT AND HUMAN MCs
To gain insights into the molecular mechanisms behind the
A3R function, the signaling pathways elicited by this receptor
were explored. These studies demonstrated that histamine release
induced by the engagement of the A3R in isolated murine lung
MCs is associated with a Ptx-and LY294002-sensitive rise in
cytosolic Ca2+ (Zhong et al., 2003). These results therefore impli-
cated Gi protein(s), phosphatidylinositol 3 kinase (PI3K) and pre-
sumably phospholipase Cβ (PLCβ) as principal mediators of A3R
stimulated degranulation in murine lung MCs. Ca2+ rise, PI3K as
well as ERK activation were also noted in BMMCs, whose FcεRI-
induced release of mediators was potentiated by the A3R (Yamano
et al., 2005, 2006). Finally, studies in RBL-2H3 cells demonstrated
A3R stimulated and Ptx sensitive activation of PLC (Ramkumar
et al., 1993) and PLD (Ali et al., 1996), rise in Ca2+, and activa-
tion of PI3K/Akt (Gao et al., 2001). Microinjection of an antibody
to either Gαi3 or Gαq inhibited the Ca2+ signal suggesting the
involvement of both G-proteins in Ca2+ mobilization (Hoffman
et al., 1997). However, since an antibody to Gαi2 was not tested,
the involvement of Gi2, that is co-expressed in MCs, cannot be
excluded. Consistent with this notion, rat A3R (rA3R), expressed
in CHO cells could interact primarily with Gi2 and Gi3 and to a
signiﬁcantly lesser extent with Gq and G11 (Palmer et al., 1995).
The pharmacological evidence for the involvement of PI3K in
mediating A3R function was further supported by genetic studies
that indicated that adenosine, acting through the A3R, transiently
increases PI(3,4,5)P3 exclusively via PI3Kγ (Laffargue et al., 2002).
Moreover,PI3Kγdeﬁcientmice did not formedema after intrader-
mal injection of adenosine or when challenged by passive systemic
anaphylaxis (Laffargue et al., 2002). Further analyses of the mech-
anisms by which PI3Kγ relays inﬂammatory signals revealed that
the p84:p110γ complex was speciﬁcally required for synergistic
adenosine-promoted degranulation and chemotaxis (Bohnacker
et al., 2009). Taken together these results are compatible with a
model (Figure 2),where by coupling toGi2/Gi3 andGq, the rodent
A3R transmits signals that effect the activation of PLCβ and PLD,
which in turn function to mediate MC degranulation (i.e., in lung
MCs) or synergize with the FcεRI-elicited signals (Kuehn et al.,
2008). In addition, activation of PI3Kγ promotes the activation of
the ERK pathway that mediates gene up-regulation and presum-
ably also the generation of arachidonic acid metabolites (Zhang
et al., 1997a,b; Sheﬂer et al., 1999) and mediates cell migration
(Bohnacker et al., 2009).
We have analyzed the signaling patterns associated with gene
up-regulation in theA3R-activated HMC-1 cells. By taking advan-
tage of ALL1, the cell permeable Gi3 inhibitory peptide, we also
assessed the role of Gi3 in mediating A3R elicited responses.
These studies revealed that Cl-IB-MECA enhances phosphory-
lation of MAP kinases, including ERK1/2, RSK1, p38α,β,γ, JNK,
and GSK3α, in an ALL1-sensitive fashion, conﬁrming the involve-
ment of Gi3 (Baram et al., 2010). Though not tested, it is tempting
to speculate that the lack of activation of PLCβ by the A3R in the
HMC-1 cells prevents them from degranulation and restricts this
receptor function to the induction of gene up-regulation and pos-
sibly the generation of arachidonic acid metabolites (Figure 2).
Interestingly, exploring the signaling patterns of the A3R in
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FIGURE 2 | Signaling pathways elicited by the human and rodent A3
adenosine receptor in MCs.This model aims to integrate the signaling
pathways reported in the literature, where marked in red are proposed, not
yet proven, pathways. According to this model, the rodent A3R couples to
Gi2, Gi3, and Gq, leading to the activation of PLD, PLCβ, and PI3Kγ. As a
result, the cytosolic concentration of Ca2+ rises and protein kinase C (PKC)
and the ERK MAP kinases are activated. According to this model, activation
of PLCβ mediates MC degranulation or synergizes with the FcεRI-elicited
signals to potentiate degranulation. PI3Kγ and ERK1/2 mediate respectively
MC migration and class II and class III mediator formation. In contrast, the
human A3R couples mainly to Gi3 leading to activation of ERK1/2 and gene
up-regulation.
BMMCs derived from a humanized mouse, in which the mouse
A3R gene was replaced by its human counterpart, revealed that
A3R activation evoked a Ptx sensitive rise in Ca2+, but failed to
enhance ERK1/2 or Akt phosphorylation, which are stimulated by
themurineA3R (Yamano et al., 2005). These results led the authors
to conclude that the hA3R couples to differentG-proteins for Ca2+
mobilization and PI3K/ERK1/2 activation (Yamano et al., 2005).
In contrast, a chimeric receptor, in which the whole intracellular
region of the hA3R was substituted by the corresponding mouse
A3R, did display identical activity to the murine A3R (Yamano
et al., 2006). Yet, the full hA3R was able to activate ERK1/2, via
PI3K, when transfected into CHO cells (Graham et al., 2001;
Schulte and Fredholm, 2002). Therefore the rodent and human
A3 adenosine receptors clearly elicit distinct signaling patterns
that are dictated by the G-protein combinations they couple to in
a speciﬁc cellular setting. Indeed, unlike most GPCRs, the rodent,
andhumanA3Rs share only 72%homology (Linden,1994).More-
over, these receptors also differ in their down-regulation patterns,
reﬂecting again their variance in partner interactions (Yamano
et al., 2005).
CONCLUSION AND FUTURE PERSPECTIVES
While the role of the rodentA3R-activatedMCs inmediatingAHR
is ﬁrmly established, the role of the hA3R in inﬂammation and
particularly in mediating MC responses remains elusive. Two rea-
sons are likely to account for the difﬁculties encountered when
studying this receptor in human samples. First, it is quite challeng-
ing to obtain and culture human MCs, thus enforcing the use of
model systems (i.e., HUCBMCs, lung derived MCs, HMC-1, and
LAD-2 cell lines), each of which having its own limitations (Hua
et al., 2011). Second, it is quite plausible that the human recep-
tor is regulated differently than the rodent counterpart, including
by more complex physiological and environmental factors. Con-
sistent with this perception is the up-regulation of the A3R in
MCs of chronic obstructive pulmonary disease (COPD) patients
(Varani et al., 2006). Indeed, unlike most GPCRs, the rodent and
human A3R share only 72% homology, while the Gi proteins are
highly conserved. Therefore, these A3Rs may couple to different
Gi proteins, thereby yielding differential signaling. In fact, the Gi
protein they couple to may vary depending on receptor occupancy
or strength of signal, resulting in differential outputs. The variance
in their amino acid sequences may also drive distinct interactions
with accessory proteins, giving rise to distinct spatio-temporal reg-
ulations. The human and rodent A3Rs may also display distinct
crosstalk with their co-expressed adenosine receptors. ATP and
ADP also activate the MCs by binding to P2 receptors. The P2
receptors are subdivided to P2X and P2Y receptors that are GPCRs
whose activation may impact MC responses. Moreover, since var-
ious combinations of P2 receptor subtypes are expressed in MCs
derived from different sources (e.g., human CBMCs, HMC-1, or
BMMCs and RBL-2H3), their contributions to the overall signal-
ing and cellular responses elicited by purinergic receptorsmay vary
accordingly (Bulanova and Bulfone-Paus, 2010). Finally, three iso-
forms of the A3R have been cloned in human and two in mouse.
Whether or not these isoforms play a role in ﬁne-tuning of the
receptor is presently unknown. It is noteworthy that the major-
ity of GPCR genes are intronless. However, for GPCRs that are
subjected to alternative splicing, the variants have proven to be
of physiological relevance (Markovic and Challiss, 2009). Hence,
an important lesson from the studies on the adenosine receptors,
at least from a therapeutic standpoint, is that the mouse stud-
ies do not necessarily predict what is happening in the human.
Thus, the question of whether an A3R agonist or rather an A3R
antagonist should be considered in asthma treatment still remains
unresolved.
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